Incannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea

Reuters03-12

Incannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea

Incannex Healthcare Inc. announced an updated clinical development plan for its obstructive sleep apnea candidate IHL-42X that includes initiating a Phase 2 crossover dose-optimization study (DReAMzz) to test multiple ratios of dronabinol and acetazolamide and select an optimal formulation. The company said it has appointed a contract research organization and expects to begin dosing patients in the coming months. Incannex plans to use results from DReAMzz to support a streamlined Phase 3 program, potentially run under a single master protocol with parallel studies, with the goal of optimizing efficacy, maintaining safety, and supporting a more efficient pathway toward potential registration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618005131?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618005131","market":"us","top_or_hot":-1,"title":"Incannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Inc. announced an updated clinical development plan for its obstructive sleep apnea candidate IHL-42X that includes initiating a Phase 2 crossover dose-optimization study (DReAMzz) to test multiple ratios of dronabinol and acetazolamide and select an optimal formulation. The company said it has appointed a contract research organization and expects to begin dosing patients in the coming months. Incannex plans to use results from DReAMzz to support a streamlined Phase 3 program, potentially run under a single master protocol with parallel studies, with the goal of optimizing efficacy, maintaining safety, and supporting a more efficient pathway toward potential registration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Inc. announced an updated clinical development plan for its obstructive sleep apnea candidate IHL-42X that includes initiating a Phase 2 crossover dose-optimization study (DReAMzz) to test multiple ratios of dronabinol and acetazolamide and select an optimal formulation. The company said it has appointed a contract research organization and expects to begin dosing patients in the coming months. Incannex plans to use results from DReAMzz to support a streamlined Phase 3 program, potentially run under a single master protocol with parallel studies, with the goal of optimizing efficacy, maintaining safety, and supporting a more efficient pathway toward potential registration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IXHL","symbol_name":"INCANNEX HEALTHCARE LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDLyFmHz:1","article_id":"2618005131","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618005131","pubTimestamp":1773317327,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea. Incannex Healthcare Inc. announced an updated clinical development plan for its obstructive sleep apnea candidate IHL-42X that includes initiating a Phase 2 crossover dose-optimization study  to test multiple ratios of dronabinol and acetazolamide and select an optimal formulation. The company said it has appointed a contract research organization and expects to begin dosing patients in the coming months. Incannex plans to use results from DReAMzz to support a streamlined Phase 3 program, potentially run under a single master protocol with parallel studies, with the goal of optimizing efficacy, maintaining safety, and supporting a more efficient pathway toward potential registration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"translate_title":"Incannex将启动IHL-42X的DREAMZZ 2期交叉剂量优化研究，并推进简化的3期计划，以实现阻塞性睡眠呼吸暂停的潜在注册","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXHL":0.9},"content_text":"Incannex to Launch DReAMzz Phase 2 Crossover Dose-Optimization Study for IHL-42X and Advance a Streamlined Phase 3 Program Toward Potential Registration in Obstructive Sleep Apnea\n    \n\nIncannex Healthcare Inc. announced an updated clinical development plan for its obstructive sleep apnea candidate IHL-42X that includes initiating a Phase 2 crossover dose-optimization study (DReAMzz) to test multiple ratios of dronabinol and acetazolamide and select an optimal formulation. The company said it has appointed a contract research organization and expects to begin dosing patients in the coming months. Incannex plans to use results from DReAMzz to support a streamlined Phase 3 program, potentially run under a single master protocol with parallel studies, with the goal of optimizing efficacy, maintaining safety, and supporting a more efficient pathway toward potential registration.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618005131","isCrawlerRequest":true}